Tenderwize
Back to tender search

Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 438 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro (ATC: A10AB04, Wirkstärke: 100 U/ml)

50/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

40 / 100

Risk factors

No estimated contract value or volume is provided, making it difficult to assess potential revenue.

The procedure is not a standard public procurement; it relies on specific SGB V and AMG provisions. The dispute resolut...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Pharmaceutical discount agreements for Insulin lispro (ATC: A10AB04, 100 U/ml)
  • Open House procedure with uniform conditions, no negotiations
Show full summary

Open House procedure by Techniker Krankenkasse and other German health insurance companies to conclude discount agreements (Rabattverträge) for Insulin lispro (ATC: A10AB04, 100 U/ml) under § 130a Abs. 8 SGB V. The procedure is open to all qualified pharmaceutical entrepreneurs, with no exclusivity, and contracts can be concluded continuously until the end date. The contract term is 24 months from November 1, 2025, to October 31, 2027. No estimated value is provided.

Risks

No estimated contract value or volume is provided, making it difficult to assess potential revenue.

The procedure is not a standard public procurement; it relies on specific SGB V and AMG provisions. The dispute resolut...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG
  • Registered office in Germany, EU, or EEA (§ 9 Abs. 2 AMG)
  • Valid marketing authorization for the product (§ 21 AMG) or equivalent right

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria specified; all qualifying participants are accepted.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro

Conclusion of discount agreements for the active substance Insulin lispro (ATC: A10AB04, 100 U/ml) under an Open House procedure. No negotiations, uniform conditions, non-exclusive.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Oct 2025 - Oct 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified; all qualifying participants are accepted.

Deadline

Deadline Oct 30, 2027

Procurement Details

Publication date
09 Sep 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
589353-2025

Documents (1)

Similar tenders